Last edition
News about "Annaliesa Anderson"
Pfizer Reports Positive Phase 2 Results for Pediatric Pneumococcal Vaccine Program
Pfizer reports strong phase 2 results for its 25-valent pediatric pneumococcal vaccine candidate, showing enhanced serotype 3 immune response, broad protection across 25 serotypes, and a favorable safety profile ahead of Phase 3 development.
Annaliesa Anderson | 20/05/2026 | By News Bureau
Pfizer-Valneva Lyme Vaccine Shows Strong Phase-III Efficacy
Pfizer and Valneva’s Lyme disease vaccine candidate showed over 70 percent efficacy in phase-III trials in individuals aged five years and above, with a strong safety profile, as Pfizer prepares for regulatory submissions, marking a key step towards potential approval.
Annaliesa Anderson | 24/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy